- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.03. | J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections | ||
| 18.03. | Aspen's fresh Parkinson's data; Aldeyra tanks following FDA rejection | ||
| 18.03. | Crossbow raises $77M for new cancer immunotherapies | ||
| 18.03. | Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers | ||
| 17.03. | Bicycle to lay off 30% of staff, pivot away from Padcev challenger | ||
| 17.03. | Pfizer's Ibrance successor moves forward with new study data | ||
| 17.03. | Federal court blocks RFK Jr.'s moves to upend US vaccine policy | ||
| 17.03. | R1 starts up with $78M, aiming for a better kidney drug | ||
| 16.03. | CytomX surges on positive data for 'masked' ADC in colorectal cancer | ||
| 16.03. | Structure's GLP-1 pill shows 'best-in-class' potential in obesity trial | ||
| 16.03. | Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy | ||
| 13.03. | With FDA go ahead, a China biotech notches a first in cell therapy testing | ||
| 13.03. | GSK's RSV vaccine wins broader FDA clearance | ||
| 13.03. | Evotec, Vistagen lay off staff; Immutep shares collapse on study failure | ||
| 13.03. | New FDA guidance could elevate pharma's biosimilar market | ||
| 12.03. | Lilly warns GLP-1 knockoffs may be 'dangerous,' escalating war with compounders | ||
| 12.03. | FDA to unify agency's 'fragmented' safety surveillance system | ||
| 11.03. | Biogen builds case for Spinraza successor with fresh data | ||
| 11.03. | FDA clears repurposed GSK drug for ultra-rare brain disease instead of autism | ||
| 11.03. | Lilly unveils $3 billion production expansion in China | ||
| 11.03. | Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial | ||
| 11.03. | With $100M, Vima pursues an oral drug for movement disorders | ||
| 10.03. | BioNTech founders to step down and helm new mRNA startup | ||
| 10.03. | Xenon hits a 'home run' in epilepsy; FDA restarts review of Duchenne cell therapy | ||
| 09.03. | Vertex kidney disease drug hits mark in late-stage study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.